221 related articles for article (PubMed ID: 17190373)
1. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation.
Cefali EA; Simmons PD; Stanek EJ; Shamp TR
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373
[TBL] [Abstract][Full Text] [Related]
2. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.
Cefali EA; Simmons PD; Stanek EJ; McGovern ME; Kissling CJ
Int J Clin Pharmacol Ther; 2007 Feb; 45(2):78-88. PubMed ID: 17323787
[TBL] [Abstract][Full Text] [Related]
3. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
4. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
Thakkar RB; Kashyap ML; Lewin AJ; Krause SL; Jiang P; Padley RJ
Am J Cardiovasc Drugs; 2009; 9(2):69-79. PubMed ID: 19331435
[TBL] [Abstract][Full Text] [Related]
5. Extended-release niacin (nicotinic acid)/laropiprant.
Perry CM
Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
[TBL] [Abstract][Full Text] [Related]
6. The effect of aspirin on niacin-induced cutaneous reactions.
Whelan AM; Price SO; Fowler SF; Hainer BL
J Fam Pract; 1992 Feb; 34(2):165-8. PubMed ID: 1737967
[TBL] [Abstract][Full Text] [Related]
7. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
Jacobson TA
Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
[TBL] [Abstract][Full Text] [Related]
10. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
11. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
[TBL] [Abstract][Full Text] [Related]
12. Validation of a questionnaire to assess niacin-induced cutaneous flushing.
Norquist JM; Watson DJ; Yu Q; Paolini JF; McQuarrie K; Santanello NC
Curr Med Res Opin; 2007 Jul; 23(7):1549-60. PubMed ID: 17559750
[TBL] [Abstract][Full Text] [Related]
13. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
Benhalima K; Muls E
Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
[TBL] [Abstract][Full Text] [Related]
14. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.
Kawata AK; Revicki DA; Thakkar R; Jiang P; Krause S; Davidson MH; Punzi HA; Padley RJ
Clin Drug Investig; 2009; 29(4):215-29. PubMed ID: 19301936
[TBL] [Abstract][Full Text] [Related]
15. Apple pectin for the reduction of niacin-induced flushing.
Moriarty PM; Backes J; Dutton JA; He J; Ruisinger JF; Schmelzle K
J Clin Lipidol; 2013; 7(2):140-6. PubMed ID: 23415433
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of extended-release niacin with laropiprant.
Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
[TBL] [Abstract][Full Text] [Related]
17. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.
Jungnickel PW; Maloley PA; Vander Tuin EL; Peddicord TE; Campbell JR
J Gen Intern Med; 1997 Oct; 12(10):591-6. PubMed ID: 9346454
[TBL] [Abstract][Full Text] [Related]
18. More on niacin: no flush, no good.
Harv Health Lett; 2007 Jul; 32(9):7. PubMed ID: 17663076
[No Abstract] [Full Text] [Related]
19. Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing.
Banka SS; Thachil R; Levine A; Lin H; Kaafarani H; Lee J
Am J Health Syst Pharm; 2017 Jun; 74(12):898-903. PubMed ID: 28432049
[TBL] [Abstract][Full Text] [Related]
20. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D
Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
